Page 167 - CL Armchair Case

On the 14 December 2015 Reckitt Benckiser was ordered

to withdraw, within three months, the current Nurofen

specific pain products from Australian shelves after a
court ruled, they had made misleading claims.

Earlier in March 2015 Australia's consumer watchdog took

court action disputing Nurofen packaging that products in

its Nurofen Specific Pain range , were formulated to treat

different types of pain, when the products contained an
identical amount of the same active ingredient, ibuprofen

lysine .

“The Federal Court ruled the British-based

multinational engaged in misleading conduct with the
main ingredient, 342 milligrams of ibuprofen lysine, the

same in all the products with none any better at treating

one type of pain than others.”

The court ordered that:

• Nurofen Back Pain,

• Nurofen Period Pain,

• Nurofen Migraine Pain and

• Nurofen Tension Headache

be removed from retail shelves within three months and

packets amended.